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Abstract
Background: Squamous cell carcinoma (SCC) of the tonsil is the most common malignant tumour of the
oropharynx. Paediatric tonsillectomy is one of the most commonly performed procedures in Otorhinolaryngology.
SCC of the tonsil remnant (SCCTR) in a previously tonsillectomised patient is rare.
Methods: Retrospective review of patients with SCCTR presenting to the Otorhinolaryngology, Head and Neck Unit
January 2000 to December 2007.
Results: Two hundred and fifty patients with tonsil SCC were identified. Ten (4%) of these had previously
undergone tonsillectomy in childhood. Nine patients underwent radical treatment including surgery, radiotherapy
and in four cases concomitant chemotherapy. Eight patients are alive with no signs of recurrence with follow-up of
a minimum of 24 months. One has been lost from follow-up.
Conclusions: Clinicians should be aware that SCC can arise from a tonsillar remnant. SCCTR has similar oncological
outcomes as tonsillar tumours.
Background
Paediatric tonsillectomy is a very common procedure
performed for a variety of indications, most commonly
to prevent recurrent acute tonsillitis. In England 51,318
tonsillectomies were performed in the year 2005/2006.
58% of these operations were in patients under the age
of fifteen [1]. The technique for tonsillectomy has
evolved over time. Recent innovations using LASER,
powered instruments and diathermy have replaced tradi-
tional cold steel methods, although these are still com-
monly used. It is well known that some techniques will
not remove the totality of the tonsil tissue and therefore
tonsillar remnant will be left. It is also known that mini-
mal remnants can re-grow due to immunological stimu-
lation [2].
The incidence of pharyngeal cancer in England is 4.0
per 100,000 with 1,339 diagnoses in the year 2000. The
most common site of cancer within the pharynx is the
palatine tonsil with just over 400 new cases per year in
England [3]. However, squamous cell carcinoma of the
tonsillar remnant (SCCTR) in a previously tonsillecto-
mised patient is rare and with only one previously docu-
mented case [4].
Pharyngeal SCC commonly spreads to the cervical
lymph nodes. At the time of presentation, 22% of patients
with pharyngeal cancer have cervical metastases [5].
However, 10% of all cervical lymph node metastases pre-
sent without a known primary site [6]. The majority of
unknown primary tumours originate from Waldeyer’s
ring [7]. Investigation protocols for the patient with cer-
vical lymphadenopathy and an unknown primary may
vary but usually comprise, fine needle aspiration cytology
with or without ultrasound guidance, cross sectional ima-
ging with Computerised Axial Tomography (CT), Mag-
netic Resonance Imaging (MRI) or both of head, neck
and chest regions and panendoscopy and biopsy of
‘at-risk’ sites including ipsilateral tonsillectomy, or bilat-
eral when indicated.
18Fluorodeoxyglucose Positron
Emission Tomography (
18FDG-PET) may be useful in the
localisation of occult primary tumours in patients pre-
senting with metastatic nodal disease in the head and
neck, although it is not yet fully utilised [8].
The incidence and biological behaviour of tonsillar
SCC has been well established and their patterns of
spread and response to conventional treatments has
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However, the incidence, biological behaviour, patterns of
spread and outcomes to treatment of SCCTR have not
been previously reported in the oncological literature.
The aim of this paper is to analyse the incidence, clin-
ical presentation, management strategies and clinical
outcomes of previously tonsillectomised patients diag-
nosed with SCCTR.
Subjects and Methods
A retrospective review of 10 patients with SCC of the ton-
sillar remnant presenting to the Otorhinolaryngology,
Head and Neck Unit at Guy’s and St Thomas’ NHS Foun-
dation Trust from January 2000 to December 2007 was
performed. All patients were seen in the Head and Neck
Oncology Unit by the senior authors and underwent a
standard protocol of investigation following The British
Association of Otorhinolaryngology Head and Neck Sur-
gery Guidelines for the management of head and neck
cancer [10]. This includes clinical examination with
fibreoptic nasendoscopy, CT of head, neck and chest, MRI
scanning where appropriate and rigid endoscopy with
biopsies of nasopharynx, ipsilateral tonsil, tongue base and
any mucosal abnormality of larynx and pharynx [10].
All patients were discussed at the multidisciplinary
head and neck oncology tumour board meeting before
their treatment was advised. All patients with Stage I
and Stage II disease had single modality treatment and
all patients with Stage III and Stage IV disease were
treated by combined modality treatment protocols
according to our standard operational policy. The onco-
logical stage of their disease was classified according to
the International Union Against Cancer (UICC) TNM
classification of Malignant Tumours (6
th edition) [11].
Results
From January 2000 to December 2007, 251 patients with
squamous cell carcinoma of the tonsil were diagnosed at
the Head & Neck Unit at Guy’s and St Thomas’ Hospital.
Ten of these patients (4%) had tonsillectomy performed
in childhood. There were seven males and three females
with a median age of 56.5 years (range 43-74 years) and a
mean of 58.1 years. Two patients were Stage II and
8 Stage IV. In five (50%) patients the index tumour was
identified on clinical examination. In the remaining
5 there was no obvious index tumour on clinical exami-
nation. They were investigated following an occult pri-
mary protocol.
In one patient the histology of the tonsil demonstrated
only carcinoma in-situ in the presence of metastatic dis-
ease in the ipsilateral lymph nodes. No invasive carci-
noma was found in a subsequent wide local excision.
One patient with T3 N3 M1 was treated with palliative
intent and the remainder underwent radical planned
combined modality treatment. Surgery to the primary
site included excision biopsy of the tonsillar remnant in
six patients, and trans-oral Potassium Titanyl Phosphate
(KTP) LASER excision in three cases. One patient had
only an incisional biopsy of the remnant due to the
large size of the tumour.
Five patients underwent modified radical neck dissec-
tion, one underwent bilateral modified radical neck dis-
section and one underwent a radical neck dissection.
One underwent an excision biopsy of the metastatic cer-
vical lymph node prior to referral. Nine patients received
radical radiotherapy to the primary site and neck
(65 Gray in 30 fractions over 6 weeks) and in addition
four patients received concomitant Cisplatin chemother-
apy (75 mg/m
2 for 3 cycles). Eight patients are alive with
no evidence of disease at a minimum follow-up of
24 months and a maximum of 10 years. One patient died
within 2 months of diagnosis as she had untreatable dis-
ease and one patient failed to attend follow-up after
12 months.
The patient’s demographic data, presenting symptoms,
TNM staging, treatment modality and Outcome are
summarized in Table 1.
Discussion
Tonsillectomy is one of the most commonly performed
operations by Otorhinolaryngologists. Techniques for
tonsillectomy have evolved and there is a possibility of
residual tonsil tissue being left in situ as a tonsillar rem-
nant. In this series all patients had their tonsils removed
in the 1950’s and 1960’s when guillotine tonsillectomy
was particularly popular. Tonsillectomy is often per-
formed by trainee surgeons. It is possible that the less
experienced surgeon might inadvertently leave tonsil
tissue in the oropharynx which might account for the
presence of remnant. It is also possible for the lymphoid
tissue in Waldeyer’s ring to re-proliferate due to immu-
nological stimulation either in the palatine tonsil or as an
expansion of the lingual tonsil[2].
SCC of the tonsil is the most common malignant
tumour of the pharynx accounting for 50% of tumours
in this site [10]. The incidence in our unit which covers
a population of 1.5 million, is comparable to previously
published data [3]. SCCTR has only been previously
described as a single case report and as such there is no
quoted incidence. Patients with SCCTR may present
with symptoms and signs of local, regional or distant
metastatic disease. In this series, three patients pre-
sented with a sore throat, one with a tonsillar mass (see
figure 1) and nine of the patients complained of a lump
in the neck. Five (50%) patients had no obvious site of
primary tumour when initially seen in clinic.
All patients with suspected head and neck malignancy
should have a full otorhinolaryngological assessment
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vious surgery has been performed, including the age of
tonsillectomy. Clinicians should be aware that previous
tonsillectomy does not preclude the possibility of a ton-
sillar remnant and this harbouring SCC. Therefore, a
high index of clinical suspicion should be exercised in
patients who had previous tonsillectomies and present
with potentially occult primary SCC of the head and
neck region.
Patients who present with a clinically obvious tonsillar
mass should undergo examination and biopsy under
general anaesthetic. The presence of malignant lateral
cervical lymphadenopathy in the absence of an obvious
index tumour represents a challenging diagnostic and
management dilemma [12,13]. In patients who have no
identifiable primary site a systematic approach with an
investigation protocol is mandatory. In our unit we fol-
low a validated protocol; namely the BAO-HNS guide-
lines for management of head and neck cancer. This
Table 1 showing results with presenting symptoms, stage of disease, management and outcome
Age at
diagnosis
(years)
Gender Presenting
symptoms
TNM
stage
Management Follow-up
(months)
Outcome
43 M Neck Mass
Unknown 1°
T1N3M0 Excision Biopsy
RND
Radiotherapy
120 Alive
67 F Neck Mass T3N3M1 Palliative care 2 Deceased
57 M Sore throat
Neck Mass
T4N2cM0 KTP
Bilateral MRND
(type I+II)
Radiotherapy
Cisplatin
Chemotherapy
Lost after
12
Alive
56 F Neck Mass
Unknown 1°
TisN2aM0 KTP
MRND (type I)
Radiotherapy
72 Alive
74 M Neck Mass
Unknown 1°
T1N1M0 Radiotherapy 84 Alive
47 M Neck Mass
Tonsil Mass
T3N3M0 KTP
MRND (type I)
Radiotherapy
60 Alive
67 F Sore throat T2N0M0 Excision Biopsy
Radiotherapy
60 Alive
56 M Neck Mass
Unknown 1°
T1N2bM0 MRND
Radiotherapy
Cisplatin
Chemotherapy
68 Alive
50 M Neck Mass
Unknown 1°
T2N2aM0 MRND
Radiotherapy
Cisplatin
Chemotherapy
48 Alive
64 M Sore throat
Neck Mass
T2N3M0 Radiotherapy
Cisplatin
Chemotherapy
Staged MRND
24 Alive
MRND - modified radical neck dissection.
RND - radical neck dissection.
Figure 1 showing T2 primary squamous cell carcinoma of the
right tonsillar fossa. The epicentre of the tumour was found to be
in the tonsillar remnant and it ulcerated through the tonsillar pillar.
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fibreoptic nasendoscopy, fine needle aspiration cytology
of the cervical lymphadenopathy and cross sectional ima-
ging with CT scanning (see figure 2) and MRI scanning
where appropriate. This is followed by upper aero-
digestive tract rigid endoscopy with biopsies of the post-
nasal space, tongue base, pyriform sinus, ipsilateral
tonsillectomy and biopsies of any suspicious focal lesions
[10]. Following this diagnostic algorithm up to 95% of
primary tumours will be found, and in 33% of cases the
index tumour will be located in the tonsil or tongue base
[14]. In patients who have undergone previous tonsillect-
omy the index tumour may be found in the tonsillar rem-
nant and this is the case in 50% of our cohort.
In our unit, radiological investigation for staging head
and neck cancer includes ultrasound (US), CT and MRI
when assessing soft tissue involvement. Ideally, diagnos-
tic imaging such as CT or MRI, should be performed
before biopsy in an attempt to identify the index tumour
and allow adequate staging of the disease [13]. Further
radiological imaging including
18FDG-PET scans may be
useful in a certain subset of patients but its usefulness,
when available, is yet to be proven especially if the
index tumour is smaller than 1 cm in diameter [15]. In
our series, all patients with an occult primary were
assessed using our standard diagnostic protocol and
18FDG-PET was not utilised.
Although the histological characteristics and aetiologi-
cal factors are beyond the scope of the present study, all
the tumours were typical of tonsillar carcinomas:
poorly differentiated squamous cell carcinomas, includ-
ing some basaloid squamous types. Figure 3a shows an
example, depicting the border between normal pharyn-
geal epithelium and carcinoma. The period of review
predated the routine staining for HPV in tonsillar
tumours but there is no reason to suppose that
SCCTR differ from conventional tonsillar carcinomas.
Immunohistochemical staining for p16, whose up-regu-
lation is a marker for transcriptionally active HPV, was
selective for the carcinoma in the same case, normal
epithelium being negative (Figure 3b). In-situ hybridi-
sation confirmed the presence of high risk HPV in an
adjacent section (Figure 3c).
Oropharyngeal carcinoma presents with clinically or
radiologically positive metastatic neck disease in
approximately 50% of cases [16]. Therefore, combined
modality therapy is considered to treat the primary site
and nodal disease. There is controversy on how this
tumour site should be managed; primary surgical resec-
tion and neck dissection followed by post operative
radiotherapy or to offer organ preservation. Our current
management strategy has evolved over the past few
years in line with current evidence based protocols. We
have therefore adopted an organ preservation protocol
involving chemo-radiation followed by staged neck dis-
section in stage III and IV disease and radiotherapy for
stage I and II disease with re-evaluation and salvage sur-
gery as appropriate. This protocol was introduced due
to previously published work which showed adverse
results due to radiotherapy delays following surgery [17].
The therapeutic strategy for patients with SCCTR will
depend on the stage of the disease at diagnosis. Patients
with proven metastatic neck disease should undergo a
combined treatment modality [18]. In our series, com-
bined treatment with surgery and radiotherapy was
employed in all patients deemed curable. Surgery to the
index tumour consisted of wide excision using a cold
steel technique or KTP LASER. The neck disease was
treated with either neck dissection combined with radi-
cal radiotherapy or radical radiotherapy alone. Four
patients received chemotherapy in addition. Using this
treatment protocol should provide cure rates of up to
70% at 5 years [19,20]. The prognosis of patients with
SCCTR may exceed this. In our series, the 2 year disease
free survival is 89% and for five years is 83%. Our series,
although limited, represents the first report of the inci-
dence, clinical presentation, management and clinical
outcomes of patients with SCCTR. It highlights the
importance of this diagnosis, which could be considered
as a clinical sub-group within SCC of the tonsil. It also
advises clinicians dealing with head and neck cancer of
the need for thorough clinical evaluation and the possi-
bility of tonsil biopsy when investigating patients
Figure 2 showing axial CT scan of necrotic right cervical
lymphadenopathy.
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childhood tonsillectomy. The management strategy for
patients with SCCTR should be the same as those as
those patients with primary SCC of the tonsil and the
outcomes for these patients appear to be similar to the
published data for SCC of the tonsil.
In conclusion, SCC of the tonsillar remnant could be
considered as a clinical sub-group within SCC of the
palatine tonsil and clinicians should be aware that carci-
nomas could arise from a tonsillar remnant. A tonsil
biopsy should be performed when investigating a patient
with an unknown primary tumour, despite childhood
tonsillectomy and a normal appearance of the tonsillar
remnant. Tonsillar remnant carcinomas appear to have
similar oncological outcomes as tonsillar tumours.
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